Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents

Abstract

Type 2 diabetes mellitus increases atherothrombotic risk. Platelets in individuals with diabetes show increased activity at baseline and in response to agonists, ultimately leading to increased aggregation. Increased expression of platelet surface adhesion molecules and receptors, enhanced production of thromboxane and thrombin and disturbances in platelet calcium homeostasis are well documented. As intra-arterial thrombi are initiated by platelets, strategies to limit acute thrombotic events have largely focused on antiplatelet agents. Aspirin remains the cornerstone of antiplatelet therapy but appears to have limited benefit in diabetes. Use of thienopyridines and platelet glycoprotein IIb/IIIa receptor inhibitors has been shown to benefit high-risk patient populations. This review summarises the different platelet abnormalities characterised in diabetes and the role of currently used antiplatelet agents.

Keywords

antiplatelet agents haemostasis platelets platelet hyperactivity type 2 diabetes

References

1. Zimmet P Alberti KG , Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782–7.

2. Kannel WB McGee DL Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 1979;2:120–6.

3. Stamler J Vaccaro O , Neaton JD , Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434–44.

4. Gurm HS Lincoff AM , Lee D et al. Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial. J Am Coll Cardiol 2004;43:542–8.

5. Lloyd-Jones DM , Camargo CA , Allen LA , Giugliano RP , O'Donnell CJ. Predictors of long-term mortality after hospitalization for primary unstable angina pectoris and non-ST-elevation myocardial infarction. Am J Cardiol 2003;92:1155–9.

6. Malmberg K Yusuf S , Gerstein HC et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000;102:1014–19.

7. Serruys PW Unger F , Sousa JE et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001;344:1117–24.

8. Pell JP Pell AC , Jeffrey RR et al. Comparison of survival following coronary artery bypass grafting vs. percutaneous coronary intervention in diabetic and non-diabetic patients: retrospective cohort study of 6320 procedures. Diabet Med 2004;21:790–2.

9. Haffner SM Lehto S , Ronnemaa T , Pyorala K , Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229–34.

10.

10. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143–421.

11.

11. Beckman JA Creager MA , Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002;287:2570–81.

12.

12. Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999;340:115–26.

13.

13. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 2001;15:44–54.

14.

14. Badimon JJ Zaman A , Helft G , Fayad Z , Fuster V. Acute coronary syndromes: pathophysiology and preventive priorities. Thromb Haemost 1999;82:997–1004.

15.

15. Kannel WB McGee LD. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979;241:2035–8.

16.

16. Sobel BE. Effects of glycemic control and other determinants on vascular disease in type 2 diabetes. Am J Med 2002;113(suppl 6A):12S–22S.

17.

17. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71–86.

18.

18. Lefkovits J Plow EF , Topol JE. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553–9.

19.

19. Colwell JA Nesto WR. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care 2003;26:2181–8.

20.

20. Davi G Gresele P , Violi F et al. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation 1997;96:69–75.

21.

21. Colwell JA Winocour PD , Halushka VP.

Do platelets have anything to do with diabetic microvascular disease?

Diabetes 1983;32(suppl 2):14–19.

22.

22. Watala C. Blood platelet reactivity and its pharmacological modulation in (people with) diabetes mellitus. Curr Pharm Des 2005;11:2331–65.

23.

23. Lindemann S Tolley ND , Dixon DA et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol 2001;154:485–90.

24.

24. Cipollone F Mezzetti A , Porreca E et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 2002;106:399–402.

25.

25. Weyrich AS Lindemann S , Zimmerman AG. The evolving role of platelets in inflammation. J Thromb Haemost 2003;1:1897–905.

26.

26. Davi G Catalano I , Averna M et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990;322:1769–74.

27.

27. Eibl N Krugluger W , Streit G , Schrattbauer K , Hopmeier P , Schernthaner G. Improved metabolic control decreases platelet activation markers in patients with type-2 diabetes. Eur J Clin Invest 2004;34:205–09.

28.

28. Vinik AI Erbas T , Park TS , Nolan R , Pittenger GL. Platelet dysfunction in type 2 diabetes. Diabetes Care 2001;24:1476–85.

29.

29. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999;354:617–21.

30.

30. Gresele P Guglielmini G , De Angelis M et al. Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. J Am Coll Cardiol 2003;41:1013–20.

31.

31. Brownlee M Cerami A , Vlassara H. Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic vascular disease. Diabetes Metab Rev 1988;4:437–51.

32.

32. Winocour PD Watala C , Kinlough-Rathbone RL. Reduced membrane fluidity and increased glycation of membrane proteins of platelets from diabetic subjects are not associated with increased platelet adherence to glycated collagen. J Lab Clin Med 1992;120:921–8.

33.

33. Ferroni P Basili S , Falco A , Davi G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2004;2:1282–91.

34.

34. Li Y Woo V , Bose R. Platelet hyperactivity and abnormal Ca(2+) homeostasis in diabetes mellitus. Am J Physiol Heart Circ Physiol 2001;280:H1480–H1489.

35.

35. Gawaz M Ott I , Reininger AJ , Neumann FJ. Effects of magnesium on platelet aggregation and adhesion. Magnesium modulates surface expression of glycoproteins on platelet. in vitro and ex vivo. Thromb Haemost 1994;72:912–18.

36.

36. Natarajan A Marshall SM , Badimon JJ , Zaman GA. Platelet-dependent thrombosis in patients with type 2 diabetes and coronary artery disease (abstract). Diabetes 2007;56(suppl 1):A181.

37.

37. Osende JI Badimon JJ , Fuster V et al. Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. J Am Coll Cardiol 2001;38:1307–12.

38.

38. Steinhubl SR Charnigo R , Moliterno JD.

Resistance to antiplatelet resistance: is it justified?

J Am Coll Cardiol 2005;45:1757–8.

39.

39. Roth GJ Majerus WP. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975;56:624–32.

40.

40. Pearson TA Blair SN , Daniels SR et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002;106:388–91.

41.

41. Colwell JA. Aspirin therapy in diabetes. Diabetes Care 2004;27(suppl 1):S72–S73.

42.

42. Algra A van Gijn J. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry 1999;66:255.

43.

43. Senior K. Aspirin withdrawal increases risk of heart problems. Lancet 2003;362:1558.

44.

44. Cubbon RM Gale CP , Rajwani A et al. Aspirin and mortality in patients with diabetes sustaining acute coronary syndrome. Diabetes Care 2008;31:363–5.

45.

45. Hayden M Pignone M , Phillips C , Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136:161–72.

46.

46. Sanmuganathan PS Ghahramani P , Jackson PR , Wallis EJ , Ramsay LE. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 2001;85:265–71.

47.

47. Sacco M Pellegrini F , Roncaglioni MC , Avanzini F , Tognoni G , Nicolucci A. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003;26:3264–72.

48.

48. Sanderson S Emery J , Baglin T , Kinmonth LA. Narrative review: aspirin resistance and its clinical implications. Ann Intern Med 2005;142:370–80.

49.

49. Hankey GJ Eikelboom WJ. Aspirin resistance. Lancet 2006;367:606–17.

50.

50. Grundmann K Jaschonek K , Kleine B , Dichgans J , Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003;250:63–6.

51.

51. Gum PA Kottke-Marchant K , Welsh PA , White J , Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961–5.

52.

52. Andersen K Hurlen M , Arnesen H , Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2002;108:37–42.

53.

53. Eikelboom JW Hirsh J , Weitz JI , Johnston M , Yi Q , Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650–5.

54.

54. Rocca B Patrono C Determinants of the interindividual variability in response to antiplatelet drugs. J Thromb Haemost 2005;3:1597–602.

55.

55. Balsano F Rizzon P , Violi F et al. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group. Circulation 1990;82:17–26.

56.

56. Jarvis B Simpson K Clopidogrel: a review of its use in the prevention of atherothrombosis. Drugs 2000;60:347–77.

57.

57. Serebruany VL MA , Pokov A , Barsness Gr , Hanley DF. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: The PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) Trial. Am Heart J 2008;155:93e91–93e97.

58.

58. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348:1329–39.

59.

59. Bhatt DL Marso SP , Hirsch AT , Ringleb PA , Hacke W , Topol JE. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002;90:625–8.

60.

60. Yusuf S Zhao F , Mehta SR , Chrolavicius S , Tognoni G , Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494–502.

61.

61. Mehta SR Yusuf S , Peters RJ et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527–33.

62.

62. Steinhubl SR Berger PB , Mann JT 3rd et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411–20.

63.

63. Chen ZM Jiang LX , Chen YP et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607–21.

64.

64. Sabatine MS Cannon CP , Gibson CM et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179–89.

65.

65. Bhatt DL Fox KA , Hacke W et al. Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. N Engl J Med 2006;354:1706–17.

66.

66. Wiviott SD Braunwald E , McCabe CH et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001–15.

67.

67. Marso SP Lincoff AM , Ellis SG et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Circulation 1999;100:2477–84.

68.

68. Lincoff AM Califf RM , Moliterno DJ et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med 1999;341:319–27.

69.

69. Bhatt DL Marso SP , Lincoff AM , Wolski KE , Ellis SG , Topol JE. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 2000;35:922–8.

70.

70. Roffi M Chew DP , Mukherjee D et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 2001;104:2767–71.

71.

71. Leonardi-Bee J , Bath PM , Bousser MG et al. Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. Stroke 2005;36:162–8.